29 Jan 2025|Noida | Amity University, Noida
Amity University organizes the 5th International Global Cancer Consortium Conference on “Advances in cancer and Cancer Immunotherapy”
Amity University Noida campus organized the 5th International Global Cancer Consortium Conference on the theme, “Advances in Cancer and Cancer Immunotherapy”, from 29th January -31st January 2025.
Addressing the gathering during the Inaugural Session, Chief Guest, Dr. Rajiv Bahl Secretary, DHR and Director General, Indian Council for Medical Research, Government of India, averred, “This is the most opportune time for organizing such conference when cancer is increasing rapidly, across the globe. Immunotherapy not only offers hope but has actually led to 25% of cancer care, however, a lot of work needs to be done in cancer treatment in India. Affordable treatment which is also high in quality must be made available to cancer patients. In addition, R&D collaboration between academia and industry is required so that new technologies and therapies can be developed.”
Sharing his words of wisdom, Dr. Ashok K. Chauhan, Founder President, Amity Education Group, stated, “This is a historical day for all Amitians since we have highly esteemed and worthy speakers who are experts in the field of cancer treatment. Amity University is committed to work for nation building through research and innovation and contribute to making India a Global Superpower by the year 2047.”
Dr. G.P. Talwar, Founder, Talwar Foundation, Neb-Sarai, New Delhi, asserted,” Development of Immuno-therapeutic approaches for treatment of Advanced stage Drugs-Resistant Terminal Cancers is essential since Immunotherapies attempt to harness the innate and adaptive immune system to attack cancer cells. Immunotherapy can boost or change how the immune system works so it can find and attack cancer cells, therefore, Immunoterapy must be a major thrust area in cancer prevention.”
Dr. Balvinder Shukla, Vice Chancellor, Amity University Uttar Pradesh said, “This is a groundbreaking conference which will help in fostering research in the field of cancer treatment. Development of the health and wellness sector is of paramount importance when it comes to achieving the vision of Viksit Bharat and the Conference will help in achieving meaningful outcomes through deliberations on relevant topics by renowned experts.”
Dr. N.K. Mehra, Vice President Indian National Science Academy, opined, “In India, the incidence of cancer cases is likely to increase from 1.46 million in 2022 to 1.57 million in 2025. Immunotherapy helps in the prevention or treatment of disease with substances that stimulate the immune response. Therefore, it is crucial to develop immunotherapy to combat the disease. Vienna is the “Mecca of Immunology” and a highly significant, International Conference on Cancer is scheduled to be held in Vienna, this year, which the researchers and scientists must attend, in order to ideate and innovate novel concepts, therapies and treatments.”
Dr. G.K. Rath, Ex-chief, IRCH All India Institute of Medical Sciences, New Delhi, said, “Cancer is the most fatal disease in India, which has left behind cardiac arrest also, however, 60% of cancers are curable, if detected at an early stage. The State of Punjab has no oral cancer, which is commendable, however, many states in India have a large number of cancer patients. The need of the hour is to focus more on new therapies and their strategic implementation in the treatment of cancer.”
Dr. Vivek M. Rangnekar, Founding Chair, Global Cancer Consortium, introduced the three-day Conference and Prof. Bhudev C. Das, Chairman AIMMSCR, welcomed the guests on this occasion. The Inaugural Session concluded with the Release of the Abstract and was attended by the scientists, researchers, and students of Amity. During the three-day Conference, Technical Sessions on themes such as “Tumor Microenvironment and Immunity”, Emerging Cancer Immunotherapy”, “Drug Resistance and Cancer Therapy”, “Cancer Biomarkers and Vaccine” and “Cancer Targeted Therapies”, will also be organized.